Core Insights - OneMedNet Corporation is set to showcase its next-generation iRWD™ platform at ISPOR Europe, which leverages the Palantir Technologies Foundry ecosystem to provide secure, regulatory-grade real-world data (RWD) through advanced AI analytics [1][3] - The company has introduced a recurring revenue model that enhances customer access to high-value RWD, featuring Live Data Feeds and AI-Driven Conversational Search, transforming static data access into dynamic, on-demand intelligence [2][7] - The healthcare sector is projected to present an estimated US$868 billion opportunity by 2030, with a significant challenge being the acquisition of high-quality, de-identified clinical multimodal data [3] Company Developments - OneMedNet's iRWD™ platform is designed to revolutionize the access and operationalization of real-world data from over 1,750 healthcare sites, providing insights that can drive innovation in drug development and patient care [4] - The platform's Live Data Feeds offer real-time streams of de-identified clinical data, while the AI-Driven Conversational Search allows users to query complex datasets using natural language, enhancing data accessibility and reducing technical barriers [7] Market Context - The AI-enabled market within healthcare is at a transformative inflection point, with responsible access to healthcare data being a key barrier to unlocking its full potential [3] - OneMedNet's collaboration with Palantir is expected to enhance its capabilities in delivering regulatory-grade, multimodal RWD with improved speed, consistency, and security [3]

Core Insights - OneMedNet Corporation has been selected by mlHealth360 as its Real-World Data provider, marking a significant milestone in the expansion of OneMedNet's subscription-based business model [1][2][3] Company Overview - OneMedNet is a leader in AI-powered Real-World Data (RWD), utilizing data from over 1,750 healthcare provider sites and 131 million+ clinical studies to support healthcare innovation [1][4] - The company’s iRWD™ platform provides regulatory-grade, de-identified imaging and clinical data, which is crucial for AI model development and validation [2][4] Partnership Details - The multi-year agreement with mlHealth360 allows continuous access to curated X-Ray and CT datasets, enhancing mlHealth360's capabilities in medical imaging [2][3] - The collaboration aims to improve patient care by providing high-quality medical imaging data, which is essential for advancing AI model development [3][6] Market Demand - There is a growing market demand for high-quality, multimodal Real-World Data that supports model training and regulatory-grade validation, highlighting the importance of partnerships with AI and analytics companies [3][4]

Company Movements - Spruce Biosciences, Inc. experienced a monumental surge, with its price jumping to $136.81, marking a 1451% increase due to the FDA granting Breakthrough Therapy Designation for its tralesinidase alfa enzyme replacement therapy for treating Sanfilippo Syndrome Type B [1][7] - OneMedNet Corporation Warrants saw its price increase by 233.17% to $0.19, related to a strategic partnership with Palantir Technologies to enhance its healthcare AI and data analytics capabilities [2][7] - OneMedNet Corporation also made notable gains, with its price escalating by 184.88% to $2.93, driven by investor optimism around its technology and the partnership with Palantir Technologies [3][7] - Society Pass Incorporated experienced a 146.18% increase in its price to $3.47, following an analyst upgrade based on the company's robust second-quarter performance and positive future outlook [4][7] - Argo Blockchain plc saw its price rise by 106.89% to $0.86, despite uncertainty over its financial future, linked to ongoing negotiations regarding a senior secured loan crucial for its recapitalization plan [5][7] Market Dynamics - The significant price movements of these companies underscore the diverse factors at play in the financial markets, including technological innovations, clinical advancements, and strategic corporate actions [6][7]

Company Developments - Advanced Micro Devices (NASDAQ:AMD) shares surged over 27% following a landmark agreement with OpenAI to deploy up to 6 gigawatts of AMD Instinct GPU power for AI infrastructure [2][3] - The initial phase includes a rollout of 1 gigawatt of AMD Instinct MI450 GPUs in the second half of 2026, with plans for further expansions across multiple generations of AMD's data center chips [2] Market Movements - Spruce Biosciences, Inc. (NASDAQ:SPRB) shares increased by 316% after receiving U.S. FDA breakthrough therapy designation for its enzyme replacement therapy for Sanfilippo Syndrome Type B [9] - OneMedNet Corporation (NASDAQ:ONMD) shares surged 143% after selecting Palantir Technologies to enhance its healthcare AI and real-world data analytics operations [9] - Society Pass Incorporated (NASDAQ:SOPA) shares rose by 113% [9] - Lixiang Education Holding Co., Ltd. (NASDAQ:LXEH) shares fell 58% [9] - Skye Bioscience, Inc. (NASDAQ:SKYE) shares dropped 54% after failing to meet primary endpoint in a study [9] - Dragonfly Energy Holdings Corp. (NASDAQ:DFLI) shares decreased by 28% following a $25 million public offering announcement [9] Commodity Updates - Oil prices increased by 0.7% to $61.28, while gold rose by 1.8% to $3,977.90 [6] - Silver traded up 1.1% to $48.485, whereas copper fell by 1.4% to $5.0365 [6]

Core Insights - OneMedNet Corp has partnered with Palantir Technologies to enhance its healthcare AI and real-world data analytics capabilities, aiming to tap into the $868 billion AI healthcare market by 2030 [1][4] - The collaboration will utilize Palantir's Artificial Intelligence Platform to integrate complex datasets and provide real-time insights, connecting with OneMedNet's extensive network [2][3] - The partnership will focus on key therapeutic areas such as oncology, cardiology, and rare diseases, providing access to over 5 billion administrative claims and 131 million clinical exams [3] Company Developments - OneMedNet's use of Palantir's platform will enable the delivery of high-quality, regulatory-compliant data at remarkable speed, facilitating breakthroughs in clinical research and AI-driven healthcare solutions [4] - Following the announcement, OneMedNet's shares surged by 46.60%, reaching $1.510 in premarket trading [4]

Core Insights - OneMedNet Corporation has partnered with Palantir Technologies to enhance the healthcare AI and Real-World Data analytics marketplace, utilizing Palantir's Artificial Intelligence Platform to support OneMedNet's iRWD™ near real-time AI powered provider network [1][2][4] Group 1: Partnership and Technology - The multi-year agreement allows Palantir's AI Platform to integrate with OneMedNet's network, which includes access to over 5 billion administrative claims and 131 million clinical exams from more than 1,750 provider sites [3] - Palantir's software aims to reduce costs and time to market for healthcare solutions, thereby improving patient outcomes [4][5] Group 2: Market Opportunity - Access to healthcare data is identified as a significant barrier to unlocking the projected $868 billion market opportunity in AI-driven healthcare by 2030 [2] - OneMedNet is positioned to leverage Palantir's advanced analytics to create scalable recurring revenue opportunities on a secure, regulatory-grade platform [2] Group 3: Operational Enhancements - The partnership will enable faster data discovery, allowing customer inquiries to be fulfilled in minutes, thus enhancing OneMedNet's competitive edge [9] - Features such as accurate data delivery, conversational search, and increased productivity through automation are expected to improve operational efficiency and reduce costs [9] Group 4: Data Security and Compliance - OneMedNet's proprietary AI algorithms will ensure the secure anonymization of clinical data, maintaining regulatory compliance and protecting against exposure of Protected Health Information (PHI) [9] - The integration of healthcare standards with Palantir's ontology will facilitate interoperable data access for life sciences users [9] Group 5: Broader Applications - Beyond healthcare, OneMedNet's AI capabilities are applicable in industries like finance, retail, and telecom, showcasing the versatility of its data anonymization technology [11]

Core Insights - OneMedNet Corporation has announced a strategic partnership with Medcase, aiming to enter the healthcare data annotation market and create a new revenue channel in the healthcare AI ecosystem [1][2][5] Market Overview - The global healthcare data annotation market is valued at $1.5 billion in 2025 and is projected to grow to $2.8 billion by 2030, indicating a significant growth phase [2] - The investment from Scale AI, amounting to $14.8 billion from Meta, has disrupted the industry, leading to an opportunity for specialized providers focused on healthcare [2] Strategic Positioning - OneMedNet will leverage Medcase's network of over 15,000 healthcare professionals to enhance its annotation services, providing regulatory-grade, de-identified Real-World Data (RWD) [3][6] - The partnership positions OneMedNet at the center of the healthcare data value chain, addressing a large unmet market need and unlocking new growth channels [5] Competitive Advantage - The combination of OneMedNet's iRWD™ platform and Medcase's annotation expertise creates a unique competitive advantage that is difficult for generalist data players to replicate [3][6] - The healthcare sector is identified as the fastest-growing and most defensible vertical within the global data annotation industry [6] Growth Potential - The demand for specialized healthcare annotation is accelerating, with a focus on meeting the unique requirements of healthcare AI developers, pharmaceutical companies, and medical technology leaders [6][7] - OneMedNet's proprietary iRWD™ platform taps into the potential of over 1,750 healthcare sites, emphasizing the importance of domain-specific data in AI model development [7]

Core Insights - OneMedNet Corporation has achieved significant adoption by a leading global medical device company, recognized for its advancements in diagnostic imaging and digital health solutions [1] - The company has established a master services agreement that allows for ongoing engagement without a fixed term, including multiple purchase orders for Real-World Data [2] - OneMedNet's ability to provide comprehensive, multimodal data sets is emphasized as a key factor in generating Real-World Evidence, which is crucial for AI model development in medical imaging [3] Company Overview - OneMedNet is positioned as a leader in harnessing Real-World Data (RWD) through its iRWD™ platform, which taps into data from over 1,750 healthcare sites [5] - The company focuses on delivering curated, de-identified datasets that empower clients to enhance AI development, clinical trial design, and healthcare outcomes [4] - Beyond healthcare, OneMedNet's proprietary AI technology is applicable in other industries such as finance, retail, and telecom, showcasing its versatility [6]

Core Insights - OneMedNet Corporation has expanded its Cardiovascular network by adding 85 new cardiovascular centers and data sources, positioning itself as one of the largest providers of Cardiovascular Real-World Data (RWD) [1][5] Industry Context - Cardiovascular diseases (CVDs) are the leading cause of death globally, responsible for approximately 19.8 million deaths in 2022, which accounts for about 32% of all global mortality [2] - The economic burden of CVD is significant, driving an estimated $320 billion annually in the United States and over $1 trillion globally in direct healthcare costs and lost productivity [2] Company Positioning - The enriched multimodal cardiovascular data network of OneMedNet is well-suited for the pharmaceutical and insurance sectors, providing real-time data that offers deeper insights into disease progression, treatment responses, and outcomes [3] - The expansion enhances OneMedNet's ability to deliver de-identified cardiovascular imaging, diagnostic reports, and electrocardiograms (ECG) at an unprecedented scale, continually updated to reflect the latest clinical insights [4][6] - OneMedNet is positioned as the premier source for high-quality, regulatory-grade cardiovascular RWD, which fuels innovation, supports clinical evidence generation, and improves patient outcomes [5] Technological Advancements - By combining de-identified cardiovascular imaging, structured reports, and ECG signals, OneMedNet provides real-world clinical insights that accelerate innovation in diagnostics, therapeutics, and AI model development [6] - The company utilizes its iRWD™ platform to harness the potential of over 1,750 healthcare sites, delivering precision insights across various medical fields, including cardiology [7]

Company Overview - OneMedNet Corporation is a leader in AI-powered Real-World Data (RWD) and has established a long-term strategic partnership with Circle Cardiovascular Imaging Inc. to enhance cardiac diagnostics and treatment planning [1][4] - Circle CVI selected OneMedNet's iRWD™ platform for access to diverse and regulatory-grade cardiovascular datasets, which includes data from over 1,750 provider sites and over 131 million exams [2][4] Partnership Details - The collaboration allows Circle CVI to expand its research and development capabilities while aligning with evolving regulatory and clinical evidence standards [4] - Circle CVI's CEO highlighted the exceptional quality and regulatory readiness of OneMedNet's data, indicating a commitment to a long-term partnership [3][5] Industry Implications - This partnership exemplifies a growing industry shift towards utilizing real-world evidence as a foundation for medical innovation [4] - OneMedNet's platform is positioned to revolutionize how healthcare companies access and utilize Real-World Data, which is critical for driving innovation in various medical fields [5]